C-Reactive Protein Testing Market on Track for Strong Growth, Estimated to Grow at 5% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the C-Reactive Protein Testing Market Through 2025?
In the past few years, the c-reactive protein testing market has seen consistent growth. It is expected to rise from a value of $3.45 billion in 2024 to $3.52 billion in 2025, experiencing a compound annual growth rate (CAGR) of 2.0%. The growth observed in the historic period can be credited to factors such as a rise in the prevalence of inflammatory diseases, assessment of cardiovascular risks, accelerated aging population, enhanced healthcare infrastructure, and the implementation of more healthcare screening programs.

What's the Projected Size of the Global C-Reactive Protein Testing Market by 2029?
In the coming years, the market size for c-reactive protein testing is anticipated to experience a steady growth. It is projected to reach $4.28 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.0%. Factors contributing to this growth during the forecast period include an increase in obesity, the rise of personalized medicine and biomarkers, advancements in telehealth and remote monitoring, early detection of diseases, and inflammation linked to lifestyle. Key trends anticipated during this forecast period incorporate advancements in diagnostic testing, the advent of wearable health technology, technological solutions, strategic partnerships, and the introduction of industry 4.0.

View the full report here:
https://www.thebusinessresearchcompany.com/report/c-reactive-protein-testing-global-market-report

Top Growth Drivers in the C-Reactive Protein Testing Industry: What's Accelerating the Market?
A surge in cardiovascular diseases (CVD) incidents is predicted to boost the c-reactive protein testing market's expansion. Cardiovascular ailments encompass heart-related issues such as diseased vessels, anatomical abnormalities, and blood clotting. The precise origin of CVD remains speculative, with numerous factors possibly elevating the potential risk. One notable factor is the behavioral risk arising from uncontrolled eating habits, insufficient physical exercises, smoking, and alcohol consumption, leading to fatty deposits buildup within the arteries (atherosclerosis), thus spiking the likelihood of blood clotting. These behavioral tendencies induce increased blood pressure, blood glucose, lipids, weight accumulation, and obesity. The upswing in heart disease cases necessitates the employment of c-reactive protein testing to ascertain or predict the probability of encountering heart complications equivalent to or surpassing cholesterol levels. To illustrate, in December 2023, as reported by the Institute for Health Metrics and Evaluation, 19.8 million global mortality incidents were due to CVDs in 2022, with ischemic heart disease making the largest proportion at 108.8 fatalities per 100,000 individuals. Elevated systolic blood pressure was the principal contributor to Disability-Adjusted Life Years (DALYs) connected to CVD, as dietary risks and air contamination emerged as significant behavioral and environmental determinants driving this global issue.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6719&type=smp

What Long-Term Trends Will Define the Future of the C-Reactive Protein Testing Market?
In the c-reactive protein testing market, a dominant trend is the continuous development in measurement devices. Major market players are concentrating their efforts on delivering progressively advanced solutions to bolster their foothold in the market. These companies employ next-generation c-reactive testing technologies in their practices and advanced solutions, offering benefits such as superior output and diverse applications. For example, in February 2022, Aidian, a Finnish firm specializing in diagnostic tests and test solutions, launched the QuikRead go wrCRP & wrCRP+Hb kits. These kits consistently generate dual outcomes a broad spectrum of CRP and Hb, from a singular sample with one analysis. The wide-range CRP test allows for CRP readings which can be used to assess conditions like neonatal sepsis, gauge disease severity in instances of COPD (chronic obstructive pulmonary disease), and help in cardiovascular risk assessment.

What Are the Main Segments in the C-Reactive Protein Testing Market?
The c-reactive protein testing market covered in this report is segmented -

1) By Assay Type: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays
2) By Application: Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, Cancer, Other Applications
3) By End Use: Clinics, Hospitals, Diagnostic Laboratories

Subsegments:
1) By Enzyme-Linked Immunosorbent Assay (ELISA): Direct ELISA, Indirect ELISA, Sandwich ELISA
2) By Chemiluminescence Immunoassay (CLIA): Luminometer-Based CLIA, Automated CLIA Systems
3) By Immunoturbidimetric Assays: Nephelometry-Based Immunoturbidimetric Assays, Latex Agglutination Immunoturbidimetric Assays

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=6719&type=smp

Which Top Companies are Driving Growth in the C-Reactive Protein Testing Market?
Major companies operating in the c-reactive protein testing market include Thermo Fisher Scientific Inc., F Hoffmann-La Roche AG, Danaher Corporation, Quest Diagnostics Incorporated, Siemens AG, Abbott Laboratories, Aidian Oy, Boditech Med Inc., Horiba Ltd., Laboratory Corporation, Merck KGAA, Randox Laboratories Limited, Getein Biotech Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., Eurofins Scientific SE, Inova Diagnostics Inc., Luminex Corporation, Sekisui Diagnostics LLC, Sysmex Corporation, Tosoh Corporation, Trinity Biotech Plc, WerfenLife Group LLC, ZEUS Scientific Inc., BioMérieux SA, Biomerica Inc., Gold Standard Diagnostics Corp., Immunodiagnostic Systems Holdings PLC, Nova Biomedical Corporation

Which Regions Will Dominate the C-Reactive Protein Testing Market Through 2029?
North America was the largest region in the c-reactive protein testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-reactive protein testing market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6719

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.